AlphaTON Capital Corp
ATON
Company Profile
Business description
AlphaTON Capital Corp is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
Contact
Clarence Thomas Building
P.O. Box 4649
Tortola
Road TownVG1110
VGBT: +1 203 221-7378
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
4
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,140.50 | 11.00 | 0.12% |
| CAC 40 | 7,656.10 | 42.82 | -0.56% |
| DAX 40 | 23,625.66 | 144.67 | -0.61% |
| Dow JONES (US) | 45,316.53 | 304.76 | -0.67% |
| FTSE 100 | 9,204.98 | 11.89 | -0.13% |
| HKSE | 25,417.98 | 359.47 | 1.43% |
| NASDAQ | 21,621.71 | 85.98 | -0.40% |
| Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
| NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
| S&P 500 | 6,464.58 | 37.50 | -0.58% |
| S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
| SSE Composite Index | 3,812.51 | 46.64 | 1.24% |